Nls Pharmaceutics Ltd (NLSP) Directors and Executive Officers

Officers & Directors

Ronen Twito, age 51, has served as Executive Chairman and Chief Executive Officer since October 2025. He has over 20 years of executive leadership experience in biotechnology and high-tech industries. His previous roles include Executive Chairman and CEO of Kadimastem, Chairman of Bubbles Intergroup Ltd, Independent Director at Mer Telemanagement Solutions Ltd, Deputy CEO and CFO at Cellect Biotechnology Ltd, Vice President of Finance at BioBlast Pharma Ltd, Deputy CEO and CFO at XTL Biopharmaceuticals Ltd, CEO of InterCure Ltd, Corporate Finance Director at Leadcom Integrated Solutions, and Audit Manager at EY. He is a Certified Public Accountant in Israel and holds a bachelor's degree in Business Administration and Accounting from the College of Management Academic Studies, Israel. Prof. Michel Revel, MD, PhD, age 87, has been Chief Scientific Officer and Director since October 2025. He previously served as Chief Scientific Officer and board member of Kadimastem since 2010 and is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research contributed to the development of Interferon-beta therapy for multiple sclerosis and advancements in human embryonic stem cell technology. He has held academic and leadership positions including Chairman of the Israel National Bioethics Council and member of the International Bioethics Committee of UNESCO. He has received the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He holds M.D. and Ph.D. degrees from the University of Strasbourg, France. Kfir Molakandov, PhD, age 48, is Vice President of Research and Development. Omri Hagai, CPA, age 40, is Chief Financial Officer. Alexander C. Zwyer, age 57, is Director and Chief Business Officer.

Nls Pharmaceutics Ltd currently has 25 employees.